Nuvectis Retained Earnings Total Equity vs Total Current Liabilities Analysis
| NVCT Stock | USD 5.04 0.24 4.55% |
Nuvectis Pharma financial indicator trend analysis is infinitely more than just investigating Nuvectis Pharma recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Nuvectis Pharma is a good investment. Please check the relationship between Nuvectis Pharma Retained Earnings Total Equity and its Total Current Liabilities accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nuvectis Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Nuvectis Stock please use our How to Invest in Nuvectis Pharma guide.
Retained Earnings Total Equity vs Total Current Liabilities
Retained Earnings Total Equity vs Total Current Liabilities Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Nuvectis Pharma Retained Earnings Total Equity account and Total Current Liabilities. At this time, the significance of the direction appears to have strong relationship.
The correlation between Nuvectis Pharma's Retained Earnings Total Equity and Total Current Liabilities is 0.74. Overlapping area represents the amount of variation of Retained Earnings Total Equity that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of Nuvectis Pharma, assuming nothing else is changed. The correlation between historical values of Nuvectis Pharma's Retained Earnings Total Equity and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Retained Earnings Total Equity of Nuvectis Pharma are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Retained Earnings Total Equity i.e., Nuvectis Pharma's Retained Earnings Total Equity and Total Current Liabilities go up and down completely randomly.
Correlation Coefficient | 0.74 |
| Relationship Direction | Positive |
| Relationship Strength | Significant |
Retained Earnings Total Equity
The portion of total equity that consists of earnings retained by the company, reinvested in its core business or used to pay debt.Total Current Liabilities
Total Current Liabilities is an item on Nuvectis Pharma balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Nuvectis Pharma are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most indicators from Nuvectis Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Nuvectis Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nuvectis Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Nuvectis Stock please use our How to Invest in Nuvectis Pharma guide.Enterprise Value is likely to gain to about 116.1 M in 2024, whereas Selling General Administrative is likely to drop slightly above 4.6 M in 2024.
| 2010 | 2022 | 2023 | 2024 (projected) | Interest Income | 4K | 149K | 475K | 498.8K | Net Interest Income | 4K | 149K | 475K | 498.8K |
Nuvectis Pharma fundamental ratios Correlations
Click cells to compare fundamentals
Nuvectis Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Nuvectis Stock Analysis
When running Nuvectis Pharma's price analysis, check to measure Nuvectis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nuvectis Pharma is operating at the current time. Most of Nuvectis Pharma's value examination focuses on studying past and present price action to predict the probability of Nuvectis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nuvectis Pharma's price. Additionally, you may evaluate how the addition of Nuvectis Pharma to your portfolios can decrease your overall portfolio volatility.